Serina Therapeutics (SER) Gross Margin (2018 - 2023)
Serina Therapeutics (SER) posted Gross Margin of 1.78% for Q4 2023, down 98.48% sequentially from 117.24% in Q3 2023, and down 8572.0% YoY from 0.02% in Q4 2022.
Serina Therapeutics (SER) Gross Margin (2018 - 2023) Analysis & Trends
Serina Therapeutics has reported Gross Margin for 6 years, with the latest figure at 1.78% in Q4 2023.
- Quarterly Gross Margin fell 8572.0% year-over-year to 1.78% in Q4 2023, while the trailing twelve-month figure through Dec 2023 was 3.24% (down 5853.0% YoY) and the FY2023 annual result came in at 3.24%, down 5853.0% from the prior year.
- Gross Margin fell to 1.78% in Q4 2023 per SER's latest filing, from 117.24% in the prior quarter.
- Over five years, Gross Margin peaked at 117.24% in Q3 2023 and troughed at 1.78% in Q4 2023.
- A 5-year average of 72.17% and a median of 84.69% in 2019 frame the typical range for Gross Margin.
- The widest YoY moves for Gross Margin: up 7280 bps in 2023, down 8572 bps in 2023.
- Over 5 years, Gross Margin stood at 85.61% in 2019, then gained by 13 bps to 96.84% in 2020, then slumped by 83 bps to 16.25% in 2021, then surged by 438 bps to 87.5% in 2022, then slumped by 98 bps to 1.78% in 2023.
- According to Business Quant data, Gross Margin over the past three periods registered 1.78%, 117.24%, and 57.14% for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Serina Therapeutics | 46.70 Mn | 23.67 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 1.78% |
| Sep 30, 2023 | 117.24% |
| Jun 30, 2023 | 57.14% |
| Mar 31, 2023 | 30.00% |
| Dec 31, 2022 | 87.50% |
| Sep 30, 2022 | 44.44% |
| Jun 30, 2022 | 50.00% |
| Mar 31, 2022 | 80.00% |
| Dec 31, 2021 | 16.25% |
| Sep 30, 2021 | 91.67% |
| Jun 30, 2021 | 64.86% |
| Mar 31, 2021 | 94.64% |
| Dec 31, 2020 | 96.84% |
| Sep 30, 2020 | 75.36% |
| Jun 30, 2020 | 93.33% |
| Mar 31, 2020 | 98.88% |
| Dec 31, 2019 | 85.61% |
| Sep 30, 2019 | 88.08% |
| Jun 30, 2019 | 86.05% |
| Mar 31, 2019 | 83.76% |